HandsOn Global Management (HGM) Limited Stock Analysis

Strong revenue growth momentum with Q3 FY2026 consolidated revenue of Rs 1,424.54 lakhs representing 145.8% YoY growth from Rs 579.53 lakhs, demonstrating market traction and successful business expansion / Strategic acquisition activity with incorporation of HealthCare Capital Holding LLC (May 2025) and acquisition of Aideo Technologies LLC (September 2025) indicating management's expansion ambitions and market opportunity identification / Unmodified audit opinion from Lodha & Co LLP on both standalone and consolidated financials, confirming absence of going concern doubts and regulatory compliance despite operational challenges / Planned material related party transactions totaling US$ 15.95 million subject to shareholder approval, suggesting deepening of strategic partnerships and business relationships that could generate future revenue synergies

Severe operational unprofitability with loss before tax of Rs 299.41 lakhs in Q3 FY2026 compared to prior year profit of Rs 147.19 lakhs, representing a Rs 446.6 lakh swing indicating deteriorating unit economics / Unsustainable cost structure with employee benefits at 95.8% of total revenue (Rs 1,364.88 lakhs) combined with other expenses of Rs 300.99 lakhs, leaving negative EBITDA of Rs 219.24 lakhs and indicating acquisition-related integration costs are uncontrolled / Negative interest coverage of -6.83x and finance costs of Rs 43.85 lakhs on operating losses demonstrate the company cannot service debt from operations and faces refinancing pressure / Minimal balance sheet cushion with total equity of only Rs 1,146.25 lakhs supporting losses of Rs 312.04 lakhs in a single quarter, implying rapid equity depletion if current operational trajectory persists / Labour law regulatory risk from four consolidated Labour Codes brought into force November 21, 2025, requiring re-evaluation of compliance costs upon notification of state-level regulations with potential material impact recognition / Related party transaction dependency with US$ 15.95 million in planned transactions across four entities, raising governance concerns and indicating reliance on group companies for business continuity

Q3 FY2026 consolidated revenue grew 145.8% YoY to Rs 1,424.54 lakhs from Rs 579.53 lakhs, showing strong demand momentum. / Nine-month consolidated revenue reached Rs 4,680.54 lakhs with a marginally positive PBT of Rs 56.62 lakhs, indicating the full-year trajectory is not uniformly loss-making. / Other income of Rs 65.94 lakhs provided partial support against operating losses in the quarter. / Statutory auditors (Lodha & Co LLP) issued an unmodified conclusion on both standalone and consolidated results, reducing accounting-quality concerns. / The company expanded its operating footprint through incorporation of HealthCare Capital Holding LLC (May 2025) and acquisition of Aideo Technologies LLC (September 2025), adding potential scale in IT/ITES.

Profitability deteriorated materially: Q3 PBT was Rs -299.41 lakhs versus Rs 147.19 lakhs profit in Q3 FY2025, and PAT was Rs -312.04 lakhs. / Margins are deeply negative, with EBITDA margin at -15.39%, operating margin at -21.02%, and net profit margin at -21.91%. / Employee cost surged to Rs 1,364.88 lakhs and consumed 95.8% of revenue, indicating weak operating leverage and cost-control pressure. / Finance risk is visible through negative interest coverage of -6.83, while finance costs were Rs 43.85 lakhs despite operating losses. / Material related party transactions totaling about US$ 15.95 million require shareholder approval, adding execution/governance risk concentration around related entities.

Strong revenue growth momentum with Q3 FY2026 consolidated revenue reaching Rs 1424.54 lakhs, representing 145.8% year-over-year growth from Rs 579.53 lakhs in Q3 FY2025 / Strategic portfolio expansion through incorporation of HealthCare Capital Holding LLC in May 2025 and acquisition of Aideo Technologies LLC in September 2025, diversifying operational capabilities / Clean audit opinion with statutory auditors Lodha & Co LLP issuing unmodified conclusion on both standalone and consolidated financial results for Q3 FY2026 / Total equity of Rs 1146.25 lakhs with share capital of Rs 1259.5 lakhs provides reasonable capital base for operations with book value per share of Rs 9.1

Severe profitability deterioration with loss before tax of Rs 299.41 lakhs in Q3 FY2026 versus profit of Rs 147.19 lakhs in prior year quarter, indicating operational distress despite revenue growth / Unsustainable cost structure with employee benefits expense at 95.8% of total revenue (Rs 1364.88 lakhs) and other expenses surging 595% YoY to Rs 300.99 lakhs, resulting in negative operating margin of -21.02% / Critical interest coverage ratio of -6.83x with finance costs of Rs 43.85 lakhs against negative EBIT of Rs 299.41 lakhs, raising concerns about debt servicing ability / Material related party transactions totaling US$ 15.95 million requiring shareholder approval across multiple entities including US$ 8.70 million with HealthAxis Group LLC and US$ 6 million with XBP Europe Limited, creating dependency and governance concerns / Regulatory risk from four Labour Codes consolidated and brought into force on November 21, 2025, with company unable to quantify full impact pending notification of rules and state-level regulations / Negative earnings per share of -2.48 for Q3 FY2026 and marginal nine-month profitability of only Rs 56.62 lakhs on revenue of Rs 4680.54 lakhs indicates persistent operational challenges throughout the fiscal year